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122 The Journal of Thoracic and CardioObjective: The predominant mechanism of early graft failure after coronary artery
bypass grafting remains in doubt. Aspirin administered in the initial hours after
coronary artery bypass grafting improves graft patency, implicating prostanoid
synthesis in the pathogenesis. We hypothesized that synergy between endothelial
disruption in the venous conduit and aspirin resistance would cause vein graft
failure.
Methods: Aspirin resistance, defined by diagnostic findings on at least two of three
separate assays, was serially assessed in 225 patients undergoing off-pump coronary
artery bypass grafting. Endothelial cell integrity was determined in surplus segments
obtained from 408 vein grafts. The deposition of intraluminal thrombin within the
vein was determined by comparing serum F1.2 levels between the coronary sinus
and the aorta after grafting. Intraoperative blood flow in the grafts was measured
with transit-time technology, and patency was assessed with electrocardiographi-
cally gated multichannel computed tomographic coronary angiography on day 5.
Aspirin was the sole antithrombotic agent used during the study.
Results: Thrombosed grafts (16/408) showed more endothelial cell loss at the time
of grafting than did those grafts that remained patent (10.8%  21.5% vs 51.4% 
39.1% integrity, P  .01). Aspirin resistance occurred in 67 patients (30%). Graft
thrombosis was associated with aspirin resistance (P .04) and reduced endothelial
integrity (P  .01). These factors coexisted in 14 of 16 grafts that failed and were
associated with elevated coronary sinus F1.2 levels.
Conclusion: Aspirin resistance and relatively compromised venous endothelial cell
integrity together marked patients whose vein grafts failed within days after off-
pump coronary artery bypass grafting. These observations form a basis for identi-
fying patients at risk and developing approaches to prevent vein injury or to
selectively intervene in high-risk circumstances.
Conditions that create nonlaminar or sluggish flow within the saphenous veingraft (SVG)—such as a large size mismatch between the conduit andcoronary target,1 intrinsic disease in the outflow bed, or an abnormal
anastomotic angle3—influence SVG thrombosis after coronary artery bypass graft-
ing (CABG). The most important cause of early attrition is thought to be inaccurate
microvascular technique, particularly for grafts performed during off-pump CABG
(OPCAB).4 However, randomized trials have shown no consistent influence of
OPCAB on SVG thrombosis.5-7 In fact, we have found that SVG grafts still fail
despite careful intraoperative screening for problems in technique with transit-time
flow measurements.8 These observations implicate alternative features in the patho-
genesis of graft thrombosis, such as conduit quality and systemic thrombogenicity.
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CDEndothelial cell (EC) integrity is known to be frequently
impaired in veins used for bypass,9 and the proportion of
denuded surface area correlates directly with reduced graft
patency.10 Aspirin, a well known therapy for preventing
graft failure,11 insufficiently inhibits platelets in many pa-
tients after cardiac surgery.12 These risk factors have rarely
been evaluated in a systematic way after CABG and never
for how they influence SVG patency in aggregate.
SVG thrombosis, variously reported at between 5%6 and
40%7 at 1 year, accounts for a substantial proportion of the
well-known limitations of long-term patency associated
with this conduit. Because of this demographically impor-
tant opportunity for practice improvement, we initiated a
prospective investigation of the mechanism of SVG throm-
bosis in patients undergoing OPCAB at a single institution.
Preliminary analysis of this data set revealed that aspirin
resistance13 and EC disruption10 were each associated with
an increased risk of acute SVG failure. The hypothesis of
this more current analysis of 250 unselected patients under-
going OPCAB was that these two risk factors interact to
promote rapid thrombin formation within the SVG, syner-
gistically increasing the risk of early thrombosis.
Patients and Methods
Patient Enrollment and Data Management
After institutional review board approval was obtained, all subjects
provided informed consent before enrollment. From November
2002 until December 2004, a total of 410 patients were screened,
and 133 patients excluded from the study for creatinine level 2.0
mg/dL (n  43), requirement for cardiopulmonary bypass (n 
37), refusal of consent (n  32), and inability to obtain valid
consent because of patient condition or emergency nature of sur-
gery (n  21). After enrollment, computed tomographic (CT)
angiography was not performed in 52 patients because of heart rate
greater than 100 beats/min or creatinine level greater than 2.0
mg/dL (n  28), patient withdrawal of consent (n  12), unavail-
ability for follow-up (n  10), and patient death without an
autopsy to confirm bypass graft patency (n  2).
Demographic data, preoperative risk factors and medications,
and intraoperative and postoperative data were prospectively re-
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CS  coronary sinus
CT  computed tomography
EC  endothelial cell
MA maximum amplitude
OPCAB  off-pump coronary artery bypass grafting
PFA-100 platelet function analyzer
SVG  saphenous vein graft
TEG  thromboelastography
WBA  whole-blood aggregometrycorded onto Teleform case report forms (TELEform Elite; Cardiff
The Journal of ThoraciSoftware Ltd, Vista, Calif), electronically scanned, and imported
into a relational database.
Surgical Technique
Four surgeons (R.P., J.B., J.G. and B.G.), experienced in OPCAB,
enrolled patients. After median sternotomy, the left internal tho-
racic artery was used in all patients; the saphenous vein was
harvested with an endoscopic (n  363 venous conduits; Vaso-
View5; Guidant Systems, Inc, Minneapolis, Minn) or open (n 45
venous conduits) approach, according to anatomic considerations.
Conduits were flushed with heparinized saline solution after har-
vest, with no methods used to control the distending pressure. The
anastomoses were performed first proximally with a partial oc-
cluding aortic clamp and then distally with suction-based exposure
and stabilizing devices (Octopus 4.3; Medtronic, Inc, Minneapolis,
Minn). Because of this protocol, little variation was present in the
length of time from when each SVG was initially placed in
solution saline storage until the proximal anastomosis was com-
pleted and the graft was reperfused with oxygenated blood (i.e.
ischemic times similar). It was reperfused with oxygenated blood
(proximal anastomosis completed). Heparin was given initially and
every 30 minutes at a dose calculated to obtain an activated
clotting time longer than 300 seconds and a heparin level of 2
IU/mL according to protamine titration (HMS heparin assay car-
tridges; Medtronic). Heparin was reversed by half the dose of
protamine calculated by heparin-protamine titration. Preoperative
aspirin (325 mg/d orally) was continued and given within 6 hours
of surgery as the sole antithrombotic agent used in the study.
Intraoperative Blood Flow Analysis
Blood flow and flow waveform were measured in each graft with
transit time ultrasonography (Transonic Systems, Inc, Ithaca, NY).
Waveforms were analyzed for pulsatility index ([maximum blood
flow  minimum blood flow]/mean blood flow) and percentage
diastolic flow with data acquisition software (WinDaq; DATAQ
Instruments, Inc, Akron, Ohio). Grafts with flow less than 10
mL/min and pulsatility index greater than 5 despite anastomotic
revision were excluded from analysis (n  2).
Immunohistochemical Staining and Enzyme-Linked
Immunosorbent Assay
Surplus segments obtained from each bypass conduit just before
the distal anastomosis were stored in Hanks balanced salt solution,
embedded in cutting compound (Tissue-Tek O.C.T., Electron Mi-
croscopy Sciences, Hatfield, Pa) and then frozen in liquid nitrogen.
The percentages of the luminal circumference staining for the
endothelial marker CD31 (R&D Systems, Minneapolis, Minn) and
tissue factor (United States Biological, Swampscott, Mass) were
analyzed as described previously10 (Figure 1).
Assays for Coagulation
Tests of coagulation (international normalized ratio, partial throm-
boplastin time, levels of fibrinogen and the peptide fragment F1.2,
and quantitative D-dimer levels) were obtained from citrated blood
samples drawn just before skin incision (baseline), just after pro-
tamine administration, and on postoperative days 1, 3, and 30.
Platelet-poor plasma was obtained from a coronary sinus (CS)
blood sample drawn by direct puncture with a 21-gauge needle
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40). F1.2 levels were obtained with an enzyme-linked immunosor-
bent assay kit (Enzygnost F1.2 Micro; Dade Behring Inc, Deer-
field, Ill) and reported as nanomoles per liter per milligram of
protein. Comparison of CS blood with a simultaneously obtained
aortic blood sample allowed the calculation of percentage trans-
cardiac change as follows: (F1.2 in CS – F1.2 in aorta)/F1.2 in CS
 100%.
Assays for Aspirin Resistance
The diagnosis of aspirin resistance was based on positive findings
consistent with this diagnosis on at least two of three of the
following assays.
Thrombelastography (TEG). We used a recently described
modification of the TEG assay (Haemoscope Corporation, Niles,
Ill) that allows clot formation to occur without thrombin genera-
tion in heparinized whole blood.14 The resulting clot maximum
amplitude in this assay with added arachidonic acid (0.5 mol/L,
MAAA) or without a platelet agonist (MA0) was compared with the
standard kaolin-activated (thrombin induced) TEG assay (MAKH).
Aspirin resistance was defined by a value greater than 50% de-
rived from a normalized formula: %MAAA  ([MAAA  MA0]/
[MAKH  M A0]) · 100%.14
Whole-blood aggregometry (WBA). Impedance changes were
assessed by WBA (Chronolog, Hawerton, Pa) at 6 minutes after
the addition of 1-g/mL and 5-g/mL collagen. Aspirin resistance
was defined as previously reported by our laboratory13 and others.15
11-Dehydro-thromboxane B2 levels. Platelet poor serum was
assayed for 11-dehydro-thromboxane B2 levels with an enzyme-
linked immunosorbent assay kit (Assay Designs Inc, Ann Arbor,
Mich). Aspirin resistance was defined as an increase in serum
levels greater than 25% relative to baseline.16
Whole-blood flow cytometry. In a subset of patients with and
without aspirin resistance, blood was incubated in the presence and
absence of arachidonic acid (1.0 mmol/L) for 2 minutes. Saturating
concentrations of fluorescently labeled antibodies that bind to recep-
tors expressed on platelets constitutively (CD41a; BD PharMingen,
San Diego, Calif) or after activation of P-selectin (CD62P; BD
PharMingen) were then added. After 20 minutes of incubation, the
124 The Journal of Thoracic and Cardiovascular Surgery ● Janusamples were fixed with 1% paraformaldehyde and stored at 4°C
to 8°C until analysis within 72 hours with a fluorescence-activated
cell sorter (Becton-Dickinson FACScan; BD Immunocytometry
Systems, San Jose, Calif). Aspirin resistance was defined as a 25%
increase in expression of the CD62P receptor after stimulation13
(Figure 2).
Postoperative Graft Follow-up
SVG patency was determined by blinded review (C.W.) of an
angiographic study acquired on a 16-slice multidetector CT scan.
The protocol for these scans and methods for determining patency
were as previously reported by our group.10,13,17
Statistics
The primary end point of this study was the risk of early graft
failure in patients with both aspirin resistance and poor EC integ-
rity in the SVG relative to patients with neither of these risks. Poor
EC integrity was defined by CD31 staining less than 25% luminal
circumference, the lowest quartile of our study population seen in
preliminary studies.8 Given that aspirin resistance occurs in as
many as 50% of patients after CABG,12 there was thus a 12.5%
risk of both aspirin resistance and poor EC integrity occurring
together, assuming these conditions to be independent. Assuming
a strong relationship between these risks and SVG failure, a
population of 210 patients was estimated to yield the minimum
number of high-risk patients needed to demonstrate a 35% differ-
ence in the rate of early graft failure at 80% power and P  .05
(UCLA Department of Statistics. Power Calculator [http://www.
stat.ucla.edu/]. Los Angeles, CA: UCLA Department of Statistics
[updated 2004 August 18]. Available from: http://calculators.stat.
ucla.edu/powercalc/).
Two-way analysis of variance was used to demonstrate a syn-
ergistic influence between risk factors on early graft failure.18 All
candidate risk variables were subjected to univariate analysis by
means of the Student t test and the Fisher exact test for continuous
and categorical variables, respectively. Multivariate analysis was
then performed to assess for interactions not detected on the
Figure 1. Surplus segments of each vein graft
were procured intraoperatively and under-
went immunohistochemical testing with
CD31 monoclonal antibody. EC integrity was
defined as percentage luminal circumference
positive for CD31 according to image analysis
software. A, As illustrated in this representa-
tive SVG section, CD31 staining was incon-
sistent on endoluminal surface of vein, sug-
gesting endothelial disruption. In contrast,
luminal staining was consistently positive in
adventitial vessels of vasa vasorum, which
were less exposed to procurement trauma. B,
With image analysis, percentage endoluminal
surface positive for CD31 was calculated. Orig-
inal magnification 10.univariate analysis. Without dropping the significant variables
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was performed by inserting all variables listed in Table 1 into the
model and accepting variables for the next step that had P values
less than .99, then .98, and then .95. A fourth analysis was
performed with a P  .05 criterion for final retention of variables.
The predictability of the model was determined by the c-statistic.
Statistical analysis was performed using the InStat (GraphPad
Software, Inc, San Diego, Calif) and MedCalc (MedCalc Software,
Mariakerke, Belgium) statistical packages with the assistance of a
biostatistician (L.N.).
The sponsors of this study had no role in the analysis or
publication of these data.
Results
Study Population
CT angiographic follow-up was complete for 225 of 277
enrolled subjects (82%). Patency of arterial grafts (n 261,
Figure 2. Whole-blood flow cytometry was used to confirm diag-
nosis of aspirin resistance by monitoring platelets (anti-CD41a,
x-axis) for change in P-selectin expression (anti-CD62P, y-axis)
in response to arachidonic acid (AA, 1.0 mmol/L). These repre-
sentative examples illustrate 30-fold increase in mean fluores-
cence intensity (MFI) for P-selectin when both TEG and WBA
were positive for aspirin resistance after arachidonic acid stim-
ulation relative to baseline. In contrast, when both functional
assays showed aspirin responsiveness, there was little change in
P-selectin after arachidonic acid.223 left internal thoracic artery, 22 right internal thoracic
The Journal of Thoraciartery, 16 radial artery) was not included in this analysis but
was 100%. Of 410 SVGs, 2 with intraoperative graft blood
flow less than 10 mL/min despite revision were excluded
from analysis. Of the 408 SVGs analyzed, 16 grafts in 16
patients were found to be thrombosed: 6 of 184 grafts to the
right coronary artery, 6 of 139 grafts to the circumflex, and
4 of 85 placed onto a diagonal coronary artery.
No differences with regards to demographic characteris-
tics, preoperative risk factors, or medication use were noted
between the 16 patients who had SVG thrombosis and those
whose grafts remained patent. Intraoperative data such as
ejection fraction, conduit diameter, target quality, and ino-
tropic requirements were also similar (Table 1).
Abnormalities in the Conduit
SVG that failed had lower intraoperative blood flow than
had those remaining patent, but the differences did not reach
statistical significance (37  29 mL/min vs 47  32 mL/
min). Pulsatility index and percentage diastolic flow, previ-
ously described proxies for grafts at risk for early closure,19-21
also failed to discriminate between grafts that thrombosed and
those that remained patent (pulsatility index 2.4 1.4 vs 2.2
 0.9, difference not significant, and percentage diastolic
flow 51%  19% vs 57%  10%, difference not
significant).
The percentage EC integrity, determined in 380 total
SVGs (191 patients), was 11% (95% confidence interval
[CI] 0.41% to 21.9%) for the 16 SVGs that failed, versus
51% (95% CI 44.2%-56.0%) for SVGs remaining patent
(P  .01; Figure 1), with no difference between open (49% 
23%) and endoscopic (51%  30%) approaches. Tissue
factor expression correlated with the EC disruption (R 
0.65, P  .01). Vein EC integrity less than 8% (first quar-
tile) coincided with a graft failure rate of 28% and with a
subendothelial pattern of expression (Figure 3).
Abnormalities in Aspirin Responsiveness
Aspirin resistance was diagnosed in 10 patients at baseline
(4%), in 22 patients (10%) on day 1, and in 67 patients
(30%) on day 3; it had resolved in all but 7 patients (2%) by
day 30. A strong correlation was seen between the platelet
response on day 3 to arachidonic acid by TEG and low-dose
collagen by WBA (percentage change in MAAA and per-
centage impedance change low and high, respectively, R 
0.72, P  .001). Patients demonstrating aspirin resistance
according to both TEG and WBA also showed a significant
rise in perioperative serum thromboxane B2 levels relative
to those with normal aspirin response (change from baseline
42%  94% vs 51%  20%, P  .001). An analysis of
platelet P-selectin expression in response to arachidonic
acid on flow cytometric analysis of an unselected subset of
20 study patients provided further confirmation of the diag-
nosis of aspirin resistance. An increase in P-selectin expres-
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6 patients with a diagnosis of aspirin resistance according to
the TEG and WBA (Figure 2). On the other hand, only 1 of
the 14 patients thought to be aspirin sensitive showed a
similar change in P-selectin expression (P  .02, Fisher
exact test). The incidence of aspirin resistance was 45%
among those found to have early graft failure, versus 20% in
those in whom all grafts were patent (P  .05, Fisher exact
test).
Abnormalities in Coagulation
Routine assays of the coagulation cascade (prothrombin time,
partial thromboplastin time, fibrinogen level, D-dimers) failed
to discriminate patients with eventual SVG failure (data not
TABLE 1. Preoperative demographic characteristics, intra
Age (y, mean  SD)
Sex (% male)
Active smoker (%)
Hypertension (%)
Previous stroke (%)
Diabetes (%)
Ejection fraction 40%* (%)
Preoperative medications
-Blockers (%)
Aspirin (%)
Angiotensin-converting enzyme inhibitors (%)
Statins (%)
Intraoperative factors
Target size 1.5 mm (%)
Poor target quality (%)
SVG/coronary diameter (%, mean  SD)
Circumflex target (%)
Wall motion abnormality absent in target region (%)†
Graft flow (mL/min, mean  SD)
SVG integrity (%CD31)
Required intra-aortic balloon pump (%)
Postoperative factors
Blood loss in 24 h (mL, mean  SD)
Given blood products (%)
Fibrinogen (mg/dL)‡
Prothrombin time (s)‡
D-Dimer (ng/mL, mean  SD)‡
Aspirin resistance at any point (%)
Aspirin resistance on day 1 (%)
Length of intubation (h, mean  SD)
Postoperative low cardiac index§ (%)
Postoperative stay (d, mean  SD)
NS, Not significant. *Ejection fraction determined by intraoperative trans
showing hypokinesis or akinesis of wall motion in myocardial region serv
postoperative period. §Cardiac index less than 2.0 L/(min · m2).shown). In contrast, transcardiac thrombin formation (as-
126 The Journal of Thoracic and Cardiovascular Surgery ● Janusessed by F1.2 levels in the CS compared with the aorta)
was significantly elevated in those patients who had SVG
failure relative to those with all patent grafts (percentage
arteriovenous difference 112%  34%, n  4, vs 19% 
41%, n  36, P  .05). Despite equivalent mean intraopera-
tive heparin levels (2.0  0.6 g/mL vs 1.9  0.4 g/mL),
transcardiac change in F1.2 was significantly increased in
patients grafted with veins in the lowest quartile of EC integrity
relative to the upper three quartiles (increase in CS vs aorta
122.4%  95.9% vs 25.4%  32.7%, P  .05).
Influence of Combined Abnormalities
on Graft Thrombosis
A total of 32 SVGs in 28 patients met the study criteria for
ative findings, and postoperative course
Status of SVG by CT angiography
ombosis (n  16) All patent (n  209) P value
67 9 69  12 NS
61 66 NS
15 25 NS
90 84 NS
16 10 NS
45 42 NS
20 18 NS
91 87 NS
90 94 NS
60 53 NS
75 78 NS
56 32 .03
25 29 NS
.78% 0.79% 2.63% 1.01% .05
38 33 NS
49 32 .08
37 29 47 32 NS
11 51 .01
18 16 NS
753 146 810 114 NS
49 57 NS
680 102 705 115 NS
12.8 0.9 13.4 0.8 NS
1954 217 1687 255 NS
45 20 .05
25 7.6 .02
17 12 16 14 NS
9 8 NS
6.1 1.1 6.2  1.9 NS
ageal echocardiography. †Intraoperative echocardiographic examination
y target coronary artery. ‡Peak (most hypercoagulable) values for entireoper
Thr
3
esoph
ed bhighest risk, EC integrity in the lowest quartile in the setting
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hospital discharge in 10 of these patients (37%; Figure 4).
Graft failure in patients with both these risk factors com-
prised a majority (63%) of the cases of graft failure, indi-
cating a positive predictive value of 63% (95% CI 35%-
85%). On the other hand, 25 patients had neither of these
two risk factors and all patent grafts, indicating a negative
predictive value of 91% (95% CI 87%-95%) and a signifi-
cant improvement in patency relative to the high risk group
(P  .001, Fisher exact test). EC disruption and aspirin
Figure 4. Although aspirin (ASA) monotherapy was sole anti-
thrombotic strategy used during this study, postoperative aspirin
resistance was significantly associated with failure only in vein
grafts in lowest quartile of EC integrity (<9%). Additionally, very
few grafts in this lowest quartile failed if aspirin sensitivity was
preserved after OPCAB. Presence of both of these risk factors
dramatically increased the risk of graft failure. Synergistic inter-
action of ASA-R and EC disruption was confirmed by paired
analysis of variance test.
The Journal of Thoraciresistance had a synergistic effect on graft failure (F score
15.91, P  .01, 2-way analysis of variance). Six variables
(listed in Table 1) were found to be different between
groups on univariate analysis. However, only three vari-
ables were retained as independent predictors after multi-
variate, logistic regression analysis: EC disruption in the
SVG, aspirin resistance on day 1, and target diameter, with
odds ratios of 5.98 (95% CI 2.15-10.46, P  .002), 2.59
(95% CI 1.13-5.95, P  .025), and 0.035 (95% CI 0.002-
0.734, P  .03), respectively. The presence of aspirin re-
sistance at any perioperative time point was excluded be-
cause of a close correlation with other independent
predictors and a model fitting strategy that discards repeated
information. The c index for the final model was 0.931.
Discussion
The major finding of this study was that insufficient sup-
pression of coagulation from aspirin (aspirin resistance)
developing early after OPCAB and EC disruption in the
SVG synergistically increased the risk of early graft throm-
bosis. In the 19th century, Virchow proposed that abnor-
malities in coagulation (eg, aspirin resistance) and EC in-
tegrity are critical factors for vascular thrombosis, yet no
previous study has established a direct link between this risk
combination and early SVG failure. Although graft failure
in the first postoperative week is frequently blamed on
surgical technique, we minimized this issue as a confound-
ing variable by the routine use of intraoperative flow mea-
surements. This protocol led to the revision or exclusion of
defective grafts at a rate consistent with previous re-
ports.19-21 Within this context, we did not find an increased
rate of early failure among grafts that were more technically
demanding during OPCAB, such as internal thoracic artery
or grafts to the circumflex artery, suggesting that we were
able to focus our analysis on risk factors related to the
conduit or patient.
Despite a well-described tendency toward EC disrup-
Figure 3. Tissue factor was constitu-
tively expressed in adventitia (thick ar-
rows) of surplus vein segments taken
from each bypass graft analyzed by
immunohistochemistry. Subendothelial
pattern of tissue factor expression (A,
arrowheads) was detected in 52 vein
segments with more severe disruption
of EC integrity (12%, 95% CI 2% to
26%). By comparison, vein segments that
did not show this pattern of tissue factor
expression (B, thin arrows) showed bet-
ter EC integrity (49.6%, 95% CI 34.4%-
60.9%, n  355).tion9,10 and a higher rate of failure than with the internal
c and Cardiovascular Surgery ● Volume 131, Number 1 127
Surgery for Acquired Cardiovascular Disease Poston et al
A
CDthoracic artery,5-7 SVG use remains prevalent because of
familiarity, convenience, and acceptable intermediate-term
results. EC injury may be caused by high-pressure saline
solution infusion, abrasion by passage of instruments through
the lumen, or by extraluminal crush injury (eg, metallic clamps
or forceps) during procurement. Immediately after grafting,
platelets adhere to collagen in the SVG exposed by EC
disruption.22 Injured veins rapidly express tissue factor,23
triggering local thrombin formation. In vitro models show
that the simultaneous exposure of platelets to collagen and
thrombin within the damaged SVG is likely to activate
platelets irregardless of aspirin use,24 setting up a positive
feedback loop for further thrombin formation.22 The peptide
fragment F1.2 is cleaved from prothrombin during the gen-
eration of thrombin and is a proven risk marker for graft
thrombosis.25 Determining the CS level of this marker may
provide a means of quantifying platelet and thrombin acti-
vation within the upstream SVG that occurs after the rever-
sal of heparin. Although ischemia and native coronary en-
dothelial disease have also been reported to affect thrombin
formation, the disrupted vein graft probably has a dispro-
portionate impact. Acute vascular injury has been shown to
be a major stimulus for regional thrombin generation in
animal models26 and in patients undergoing intracoronary
stenting.27
Early SVG failure most often occurs without detect-
able signs or symptoms, which limits understanding
about its exact timing. For practical reasons, we mea-
sured the CS F1.2 level 30 minutes after heparin reversal.
The notion that this type of intraoperative assessment is
able to reliably discriminate the risk of SVG thrombosis
remains speculative. However, evidence suggests that the
risk of thrombosis is maximal at initial graft perfusion.
First, platelet inhibition improves graft patency only
when given early postoperatively. Randomized trials
have shown that aspirin initiated 48 hours or later after
CABG does not influence the frequency of new SVG
occlusions.11 Second, EC healing of the SVG also occurs
within 2 to 3 days,28 suggesting that the impact of SVG
injury during procurement subsides within this same
early timeframe. The ability of CS F1.2 levels immedi-
ately after OPCAB to serve as an integrated predictor of
early SVG failure requires confirmation in future multi-
variate analysis from our ongoing study.
The importance of EC disruption and aspirin resistance
suggests that less traumatic vein harvesting and alternative
antithrombotic strategies might help to improve patency.
Avoidance of pressure injury during preparation of the SVG
could reduce the expression of tissue factor23 and thus throm-
bin formation after perfusion. Heparin minimizes thrombin
formation during cardiopulmonary bypass29 but did not do so
within the SVG during this OPCAB study. An agent that is
able to inhibit clot-bound thrombin, such as bivalirudin,
128 The Journal of Thoracic and Cardiovascular Surgery ● Janumay provide more effective intraoperative anticoagulation
for the SVG graft. Bivalirudin improved SVG patency in a
randomized comparison with heparin during OPCAB.30
Perhaps by inhibition of the thrombin receptor on the plate-
let, intraoperative aprotinin use may provide another ad-
junct to promote SVG patency.31 Finally, clopidogrel more
effectively inhibits platelets exposed to both collagen and
thrombin in vitro than does aspirin.22 However, clopidogrel
increases the risk of bleeding and potentially of death after
cardiac surgery.32 Targeting clopidogrel to only those with
increased transcardiac thrombin formation might provide a
rational basis for accepting that risk.
The lack of clinical validation of our methods is the main
limitation of this study. First, the best diagnostic test for
aspirin resistance remains uncertain. We addressed this
problem by considering the diagnosis of aspirin resistance
to be established only if findings were compatible in two of
three separate assays performed in all patients. The strong
correlation between the complementary methods used to
diagnose aspirin resistance and flow cytometry, a more
established method of quantifying platelet function, justifies
confidence regarding our diagnostic criteria. Second, be-
cause the risk for early SVG failure is not limited to the
period before hospital discharge, most previous studies
investigating early graft patency have obtained angiog-
raphy at 1 to 3 months. Our protocol of predischarge CT
tomographic angiography provided a higher and more uni-
form follow-up, which we considered an acceptable trade-
off. Finally, determining EC integrity on the basis of biopsy
samples from the distal portion of each graft may not
accurately reflect heterogeneous damage to other portions of
the vein. Differential handling of the actual conduit used for
bypass than of the discarded, surplus segments that were
analyzed might augment the tendency of our report to
overestimate the severity of EC injury. Future emphasis in
this ongoing study will be placed on real-time methods of
assessing EC integrity in the whole graft and on longer term
follow-up of patency. Although mechanistically consistent,
our data on regional thrombin formation as a cause of graft
failure should be considered only as hypothesis generating
pending prospective confirmation with these methodologic
improvements.
In conclusion, in this study the combination of acquired
aspirin resistance and EC disruption was strongly associated
with intraluminal thrombin generation and the risk of early
vein graft thrombosis. Exposed collagen and tissue factor
within the damaged vein may create a regional burst in
thrombin formation that contributes to the development of
aspirin resistance. We studied only patients undergoing
OPCAB order to eliminate potential confounding vari-
ables associated with cardiopulmonary bypass. However,
these data suggest that aggressive prevention, directed by
screening for conduit EC damage and transcardiac coag-
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CDulation pathway activation, may provide the best method
for improving vein graft patency after CABG, on pump
or off.2
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Discussion
Dr Steven Bolling (Ann Arbor, Mich). Poston and coauthors
should be congratulated. They have demonstrated satisfactory ev-
idence to support their conclusion that the combination of aspirin
resistance and endothelial disruption lead to early graft failure. I
have a number of questions.
Dr Poston, you used a somewhat complicated method to deter-
mine aspirin resistance involving TEG, WBA, and then flow. As
you know, it is somewhat controversial to determine aspirin re-
sponsiveness. Did you not consider a more sensitive assay, such as
platelet function analyzer (PFA-100), which can show aspirin
resistance and aspirin semiresponsivenesss?
Second, did you think that in many of these patients there may
be genetic polymorphism, especially at the P1A2 receptor, that can
be measured in these patients to determine aspirin responsiveness?
Third, have you changed your clinical practice because of this
study? Are we to measure F1.2 in terms of thrombin generation?
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clinical use of aspirin for these patients?
Dr Robert S. Poston, Jr (Baltimore, Md). With regard to the
first question about the best diagnostic method for aspirin resis-
tance, clearly you have hit on a valid issue. The best method to
diagnose aspirin resistance is not clear. We chose our assays on the
basis of them being conducted at point of care, and the PFA-100
that you mentioned is a promising test that also is at point of care.
I think that is critical if we want to have these assays be clinically
relevant and translate into clinical care.
Probably the best, most accurate method of diagnosing aspirin
resistance is flow cytometry, but that is never going to be a
clinically validated assay because it takes a 2- to 3-day turnaround,
at best, to do such assays. So a point-of-care test that can yield
results in 20 or 30 minutes is, I think, mandatory.
The PFA-100 is nice because it has a shear effect that induces
platelet reactivity and is probably more relevant for the surgical
patient. We didn’t use it in our particular series of studies here
because we were fairly convinced with our diagnostic method. We
used, as we said, two point-of-care tests that correlated well with
each other. They correlated with a clinical event that happens fairly
frequently, graft thrombosis, and also correlated with the more
sensitive measures we had, flow cytometry and thromboxane for-
mation. So we felt good about our method of diagnosis. Certainly
there are other assays that may be as good.
The second issue is the genetics. I think that is a critical point
as well. If you want to devise a strategy to improve outcome, it is
probably best to know beforehand whether aspirin resistance is
going to develop, according to genetics or an understanding of the
mechanism of aspirin resistance, and stop it before it occurs rather
than to try to change your management after detecting it in a
postoperative period. So that is the plan of our group, and we have
those studies ongoing.
With regard to changing clinical practice, we are not approved
by the institutional review board to use these results to change
practice, but that is a plan in the future. I think that assessing F1.2
in the CS, because it seems to integrate all of the risk factors for
graft failure, would be an important trial to do in the future, and
with care adjusted according to the results of that assay.
Finally, with regard to aspirin use versus other antiplatelet
agents, we desperately need agents other than aspirin because of
this concern about the development of aspirin resistance after
surgery. I don’t think clopidogrel (Plavix) is the answer. The
130 The Journal of Thoracic and Cardiovascular Surgery ● Janutherapeutic window of clopidogrel is poor. You have to load it.
Many surgeons just use a standard 75-mg dose.
A recent article in this Journal said that this doesn’t affect
platelet function, and we found that as well, that if you don’t give
a loading dose at 1 and 2 weeks out, you have no effect on
aggregation in a surgical patient. It is different in a patient who
hasn’t undergone surgery, which is where our belief that 5 days
with 75 mg is all you need to get an effect. That is where that
comes from.
There are companies that are working on an intravenous form
of a clopidogrel analog that is short acting, and I think that has a
lot of promise. Also, there may be strategies other than hepariniza-
tion with bivalirudin that might have some more effect on throm-
bin generation in the graft as well.
Dr Frank Sellke (Boston, Mass). In follow-up to your last
statement, is there any evidence that those patients who have or are
suspected of having aspirin resistance have improved graft patency
with the addition of clopidogrel? Looking at direct platelet func-
tion, there doesn’t seem to be any difference, but has anybody
looked at actual graft patency in these patients?
Dr Poston. The only thing that patients used in this trial was
aspirin. So I can’t answer that from my own data. Your point is
that there are no data indicating that clopidogrel improves patency.
I think that is a valid point, mainly because it hasn’t been used the
way it should be used, which is as a 300-mg or perhaps even
600-mg load in the immediate postoperative period. So I think
using it at 75 mg/day, the way it is in common practice, is not
likely to have an effect. I do think that it is going to be important
to have a better antiplatelet therapy titrated according to some kind
of platelet function analysis or coagulation analysis to optimize our
results.
Dr Guo-Wei He (Hong Kong, China). Since arterial grafting
does not reach 100% patency rates, do you think aspirin resistance
is also related to the occlusion of the arterial graft such as a free
graft of the radial artery as well?
Dr Poston. Well, we used arterial grafts in this study. We
didn’t report it. Every one of our arterial grafts was patent. So I
can’t relate aspirin resistance to arterial graft problems. I think that
probably based on my finding that there wasn’t any influence of
aspirin resistance on arterial graft patency that probably when
arterial grafts fail it is technical, more likely, than it would be with
a vein, which has a lot more thrombogenicity than an artery, and
so the role of aspirin resistance and graft thrombogenicity plays a
higher role with the vein.
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